Prostate-Specific Antigen
OtherWhat is Prostate-Specific Antigen?
Prostate-specific antigen (PSA) is a serine protease glycoprotein produced almost exclusively by the epithelial cells of the prostate gland. Its physiological function is to liquefy the seminal coagulum after ejaculation, facilitating sperm motility. PSA circulates in the blood in two main forms: complexed PSA (bound to alpha-1-antichymotrypsin and other protease inhibitors, comprising 70–90% of total PSA) and free PSA (unbound, comprising 10–30% of total PSA). Total PSA measures both forms combined. Small amounts of PSA normally leak into the bloodstream, and the level reflects prostate size, integrity, and pathology.
PSA is the most widely used biomarker for prostate cancer screening and monitoring, though it is organ-specific rather than cancer-specific—any condition affecting the prostate can elevate PSA. Since its introduction in the late 1980s, PSA screening has been one of the most debated topics in medicine. While PSA screening can detect prostate cancer early, many detected cancers are indolent and would never cause harm, leading to potential overdiagnosis and overtreatment with significant side effects (incontinence, erectile dysfunction). Current guidelines from the AUA and USPSTF recommend shared decision-making for PSA screening in men aged 55–69, weighing individual risk factors and values.
Why It Matters
PSA remains the cornerstone of prostate cancer detection and monitoring despite its limitations. An elevated PSA can lead to biopsy and early detection of aggressive prostate cancer, which is curable when caught early—the 5-year survival rate for localized prostate cancer exceeds 99%. PSA is also essential for monitoring men with known prostate cancer: after radical prostatectomy, any detectable PSA suggests recurrence; after radiation therapy, a rising PSA (biochemical recurrence) triggers further evaluation. PSA kinetics—including PSA velocity (rate of change over time) and PSA doubling time—provide additional prognostic information. Free PSA percentage helps distinguish cancer from benign conditions: a lower free PSA percentage (<10%) increases cancer suspicion, while a higher percentage (>25%) suggests benign disease.
Normal Reference Ranges
| Group | Range | Unit |
|---|---|---|
| Men 40–49 years | 0–2.5 | ng/mL |
| Men 50–59 years | 0–3.5 | ng/mL |
| Men 60–69 years | 0–4.5 | ng/mL |
| Men 70–79 years | 0–6.5 | ng/mL |
| General screening threshold | <4.0 | ng/mL |
Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.
What High PSA Levels Mean
Common Causes
- Prostate cancer
- Benign prostatic hyperplasia (BPH)—the most common cause of mild PSA elevation
- Prostatitis (bacterial or non-bacterial)
- Urinary tract infection
- Recent ejaculation (can raise PSA for 24–48 hours)
- Vigorous exercise, particularly cycling
- Recent prostate biopsy or cystoscopy
- Urinary retention
- Increasing age and prostate size
Possible Symptoms
- PSA elevation itself is asymptomatic—it is detected through blood testing
- Prostate cancer: often asymptomatic early; advanced disease may cause urinary difficulty, bone pain, weight loss
- BPH: urinary frequency, urgency, weak stream, nocturia, incomplete emptying
- Prostatitis: pelvic pain, painful urination, fever (if bacterial)
What to do: An elevated PSA warrants careful evaluation. Your doctor will consider your age, race, family history, PSA trend over time, and digital rectal exam findings. Additional tests may include free PSA percentage (low free PSA increases cancer suspicion), PSA density (PSA divided by prostate volume), 4Kscore or PHI (Prostate Health Index), and prostate MRI. If cancer risk is sufficiently elevated, a prostate biopsy (ideally MRI-guided) is performed. Not all elevated PSAs require biopsy—active surveillance with repeat PSA testing is appropriate in many cases.
What Low PSA Levels Mean
Common Causes
- 5-alpha reductase inhibitors (finasteride, dutasteride) reduce PSA by approximately 50%
- Obesity (dilutional effect from larger blood volume)
- Certain herbal supplements
- After radical prostatectomy (PSA should be undetectable)
Possible Symptoms
- Low PSA does not cause symptoms
- Low PSA is generally reassuring regarding prostate cancer risk
What to do: If taking finasteride or dutasteride, the PSA result should be doubled for accurate interpretation. Very low PSA in a man not on these medications is reassuring. After radical prostatectomy, PSA should be undetectable (<0.1 ng/mL); any rise above this threshold suggests biochemical recurrence. No intervention is needed for naturally low PSA levels.
When Is PSA Testing Recommended?
- As part of shared decision-making for prostate cancer screening in men aged 55–69
- Earlier screening (age 40–54) for high-risk men (African American, family history of prostate cancer)
- When prostate symptoms are present (urinary difficulties, pelvic pain)
- For monitoring after prostate cancer treatment (surgery, radiation, hormonal therapy)
- When evaluating suspected prostatitis
Frequently Asked Questions
Related Biomarkers
Want your PSA levels analyzed?
Upload your lab results for an instant AI-powered breakdown of all your biomarkers.
Upload Lab Results →Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.